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CD9 antigen (~24) was purified from human platelets and partially characterized. The yield was 75 pg from 10 units of platelet concentrates. p24 
(38 000 copies/platelet) has intramolecular disulfide bond(s) and, in SDS-PAGE, consists of major 24-kDa molecule and minor 26- to 31-kDa mole- 
cules. The N-terminal sequence of p24, PVKGGTKXIKYLLFGFNFIF, indicates that the protein has not previously been characterized and amino 
terminus (position 12-20) is hydrophobic. 
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1. INTRODUCTION 2. EXPERIMENTAL 
CD9 antigen (~24) was first described on common 
acute lymphoblastic leukemia (CALL) cells [l] but is 
also found on other hematopoietic cells including 
platelets and megakaryocytes [2-41 as well as non- 
hematopoietic cells [3]. We and others previously 
reported that monoclonal antibodies against p24 (CD9 
cluster) caused direct activation of human platelets 
leading to aggregation and granule secretion [2,5-71 or 
intrinsic protein phosphorylation [8,9]. Although 
several groups reported that p24 is involved in Ca2+ 
flux [lo] and that it has protein kinase activities 
[ 1 l-131, the precise functional role of this protein still 
remains unknown. 
2.1. Materials 
Triton X-l 14, NaBr-activated Sepharose 4B, ovomucoid trypsin 
inhibitor, and phenylmethylsulfonyl fluoride (PMSF) were purchased 
from Sigma Chemical Co. (St. Louis, MO). 
2.2. Preparation of TP82 monoclonal antibody and immunoaffinity 
column 
TP82 antibody (IgGi) obtained from murine ascites was purified 
by ammonium sulfate precipitation followed by DEAE 
chromatography [2]. Purified TP82, MM10 monoclonal antibody 
(anti-smooth muscle myosin antibody, IgGi) [18] and mouse IgG 
(Sigma) were dialyzed against 0.2 M NaHCOs (pH 9.5) and coupled 
to NaBr-activated Sepharose 4B as previously described [18]. 
2.3. Purification of CD9 antigen 
One of our concerns is whether or not p24 has 
transmembranous portion since TP82 antibody against 
p24 causes the signal transduction in platelets, i.e. 
diacylglycerol formation [3] and increases intracellular 
Ca2+ (Yatomi, Y., unpublished data). Newman et al. 
[14] reported that p24 is a non-integral plasma protein 
by using a lipophilic labeling technique [5]. LeBien et 
al. [15] and Seehafer. et al. [16,17] proposed that 
palmitylation of p24 may play a role in its function 
perhaps by alteration its positional configuration to re- 
main attached to the cell surface. To gain further in- 
sight into the molecular characteristics of this protein, 
we purified p24 from human platelets using TP82 af- 
finity column and analyzed certain biochemical proper- 
ties including N-terminal amino acid sequence. 
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Twenty units of washed platelets were resuspended in 1 vol. of buf- 
fer A (0.5 M KCl, 0.15 M potassium phosphate, pH 6.8, 2 mM 
EGTA, 2 mM EDTA, 0.2 mg/ml trypsin inhibitor, 50 fig/ml PMSF, 
3 mM DTT) and sonicated for 5 min. Two vols of buffer A were then 
added. After 1 h of extraction, the sample was centrifuged at 
48000 x g for 120 min at 4°C. The pellet was resuspended with buf- 
fer B (0.15 M NaCl, 30 mM Tris-HCl, pH 7.5, 1 mM EGTA, 
0.1 mg/ml trypsin inhibitor, 50 fig/ml PMSF) with 1% Triton X-l 14 
using glass homogenizer and dialyzed against buffer B overnight. 
After spin at 30000 x g for 30 mitt, the supernatant was first 
chromatographed on the mouse polyclonal IgG column (8.5 mg, 
10 ml) connected with MM-10 column (5 mg, 5 ml), then subjected 
to TP82 column (12 mg, 5 ml). The TP82 column was washed with 
3 vols of buffer C (0.15 M NaCl, 30 mM Tris-HCl, pH 7.5, 1 mM 
EGTA), and then 2 vols of buffer C with 1 M NaCl to remove the 
non-specific binding molecules. The bound proteins (crude ~24) was 
eluted with 3 M NaSCN, 30 mM Tris-HCl, pH 7.5. Enzyme-linked 
immunosorbent assay (ELISA) revealed that p24 was undetectable in 
both flow-through fractions and 1 M NaCl fractions. CD9-positive 
fractions (-16 ml) were collected and dialyzed overnight against 
20 mM NaCl, Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM DTT over- 
night. The samples were filtrated through 0.45 pm Millipore filter, 
applied to a TSK-DEAE-SPW column (7.5 x 75 mm) equilibrated 
with the dialysis buffer, and eluted with a linear gradient of 
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0.02-0.50 M NaCI, 2 x 16 ml, using Toso HPLC system. 
CD9-positive fractions (0.3 - 0.4 M NaCI) judged from ELISA were 
collected, dialyzed against buffer D (0.4 M NaCl, 30 mM Tris-HCl, 
pH 7.5, I mM EDTA), applied to TSK-4000 SW HPLC column 
equilibrated with buffer D. CD9positive fractions judged from 
ELISA were collected, dialyzed against 0.15 M NaCl, 30 mM Tris- 
HCl, pH 7.5 and stocked at 4°C. 
2.4. Binding assay 
Purified TPS2 was labeled with Na12’I (Amersham Corp.) to a 
specific activity of 10 yCi/pg protein by the chloramin-T method 
1191. Free and cell-bound ‘*‘I-TP82 were separated by centrifugation 
through 25% sucrose. Non-specific binding was determined by ad- 
ding a lOO-fold excess of unlabeled TP82 antibody and Scatchard 
analysis was performed [ZO]. 
2.5. N-terminal sequence 
Fifty ~1 of TCA was added to 200 al purified p24 (200 rglml). 
After spinning, the pellet was dissolved in 30 ~1 of 0.1% SDS and ap- 
plied onto an Applied Biosystems 477A Sequencer. PTH amino acids 
obtained from the sequencing were analyzed with an Applied 
Biosystems 120A. 
2.6. Phase extraction 
Detergent phase extraction was performed according to the method 
of Bordiger et al. (211 modified by Newmann et al. [22]. Briefly, 5 x 
10’ platelets were solubilized with 0.15 M NaCl, 30 mM Tris-HCl, 
pH 7.5, 1% Triton X-114 and centrifuged at iOOOO0 x g for 60 min 
at 4°C. 200 pl of the supernatant (whole lysate) was carefully applied 
to the top of a 300 hl6% sucrose cushion in a 1 ml polystyrene Fisher 
centrifuge tube [22]. The tube was warmed for 5 min at 37’C, and 
then centrifuged for 5 min at 2000 x g. The aqueous phase was 
removed, cooled to O”C, re-extracted by 1% Triton X-114 and cen- 
trifuged as above. The detergent phases from both tubes were com- 
bined and the volume adjusted to 200 ~1 by adding Hepes-Tyrode’s 
buffer. The detergent phase and whole lysate were coated with ap- 
propriate dilution to the %-well plates and measured for p24 titer by 
ELISA. 
2.7. Others 
ELISA was performed as described previously [18]. The absorp- 
tion at 492 nm was measured using Immuno-Reader MR700 
(Dainatech Laboratories Inc.). Immunopr~ipitation was performed 
as previously described [Z]. Protein concentrations were estimated by 
the method of Bradford [23] using bovine serum albumin (Bio-Rad) 
as a standard. 
TP82 added h&?/ml) 
Fig. 1. “‘I-TP82 IgG binding on human platelets. 5 x 10’ platelets 
were incubated with “‘1-TP82 antibody for 30 min at 22°C. The 
inset represents a Scatchard plot of the binding data. 
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Fig. 2. Purification of p24 from human platelets. (A) Elution profile 
of TP82 affinity column. The flow rate was 25 ml/h. (B) Elution 
profile of DEAE-SPW HPLC column (0.49 ml each). The flow rate 
was 0.7 ml/min. Inset shows SDS-PAGE (15%) of fractions from 
DEAE-HPLC column. Lanes l-4 represent he fractions 38, 40, 42 
and 44, respectively. (C) Elution profile of TSK-~SW HPLC 
column. The flow rate was 0.7 ml/min. Ten-fold diluted samples 
from each fraction were coated onto the plates and ELISA was 
performed (A---A, OD492 nm). The protein concentration was 
determined by the method of Bradford @----a, OD59f nrn) or 
OR280 nm (-). 
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3. RESULTS 
3.1. Binding of TP82 to platelets 
Fig. 1 shows representative data of the specific bin- 
ding of *251-labeled TP82 to platelets, The binding was 
complete after 20 min and reached a plateau at 3-4 pg 
per lo8 platelets. The Scatchard analysis indicated that 
TP82 binds to 38000 f 4200 sites/platelet (mean + SD, 
n = 4) with a dissociation constant (&) of 15.5 f 
2.5 nM/l (mean + SD, n = 4) of a single class of bin- 
ding site. 
3.2. Purification and biochemical characterization of 
CD9 antigen (‘24) 
TP82 affinity column (Fig. 2A) followed by 
DEAE-SPW HPLC column (Fig. 2B) were used to 
purify ~24, Further purification was performed by us- 
ing TSK-4000SW HPLC column (Fig. 2C). ~24 was 
eluted near the void volume probably because of the 
micelle formation. The yield was about 75 ,ug from 10 
units of platelets. The purity was over 90% judged by 
densitometric scanning of SDS-PAGE. The purified 
~24 inhibited TPS%-induced platelet aggregation and 
ATP release in a dose-dependent manner and this in- 
hibition was overcome by increasing the concentration 
of antibody (data not shown). 
An interesting finding is that purified ~24 is always 
accompanied by a broad band of 26- to 31-kDa pro- 
teins. The silver staining revealed that this minor band 
consists of 3-4 small bands (Fig. 3A). However, early 
portions of p24-positive fractions of DEAE contain 
much of 26-kDa protein as compared with later por- 
tions which contain major 24-kDa and minor 29- to 
3 1 -kDa proteins (inset in Fig. 2B), indicating that these 
24-kDa, 26-kDa and 29- to 31-kDa proteins have dif- 
ferent affinity to DEAE-gel. 
In a previous report [2], we showed that the 
molecular mass of iodinated ~24 immunoprecipitated 
with TP82 was 23 kDa under reduced and 24-kDa 
under non-reduced conditions. Purified ~24 also show- 
ed a small apparent increase in mobility (0.5-l .O kDa) 
under reduced conditions (Fig. 3B), suggesting the 
presence of intramolecular disulfide bond(s). The dif- 
fuse appearance (26- to 31-kDa) detected by a longer 
exposure of immunoprecipitated molecules (Fig, 3B) is 
consistent with minor bands of silver-stained ~24 
(Fig. 3A). 
N-terminal sequence (20 amino acids) was analyzed 
in two samples prepared separately. The results were 
identical (Fig. 4). No PTH amino acid was identified 
for portion 8. Computer searches (NBRF Protein Data 
Bank) revealed no significant homology with known 
proteins, although there was 40% homology in N- 
terminal sequence (20 amino acids) with that of 
melanoma-associated antigen [24,25] (Fig. 4). An in- 
teresting point is that N-terminal sequence has a 
hydrophobic region (hydropathy index 1261 is -0.84 
(position l-7); 1.56 (position 9-20); 2.16 (position 














Fig. 3. SDS-PAGE of purified ~24. (A) SDS-PAOE (12.5-20% gradient) of purified p24 (10 pg). Lane 1, Coomassie blue staining (non-reduced). 
Lane 2, silver staining of lane 1. p24 consists of major protein of 24 kDa (A) and minor proteins of 26 kDa (A) and 29 to 32 kDa (e). (B) SDS- 
PAGE (12%20% gradient) of purified and immunoprecipitated ~24. Lanes 1 and 2, purified p24 (silver staining); lanes 3 and 4, autoradiogram 
of immunoprecipitated ~24; lanes 1 and 3, reduced; lanes 2 and 4, non-reduced. In lanes 3 and 4, there are a major band (A) and diffuse minor 
band (A) as well as a few non-specific bands including 66 kDa proteins. 
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Fig. 4. Alignment of the N-terminal amino acid sequence of ~24. The 
sequence of the 20 amino acids of p24 is compared with that of 
melanoma-associated antigen (MAA). Boxed residues are identical. 
12-20)), suggesting that at least position 12-20 of N- 
terminal amino acids is a part of putative transmem- 
brane domain, although hydrophobicity plot analysis 
[26] could not be performed at present. To confirm the 
hydrophobicity of ~24, we applied the phase extraction 
technique using the non-ionic detergent Triton X-114 
following a temperature-dependent phase separation 
[21,22]. Most of p24 (85 f 6% (mean k SD, n = 5) was 
fractionated into the Triton X-114 fraction (detergent 
phase). Purified p24 was dissolved in 1% Triton X-l 14 
solution and analyzed in the same way. Similar extent 
of p24 (79 + 5% (mean f SD), n = 7) was fractionated 
into detergent phase. 
4. DISCUSSION 
The number of binding sites of TP82 IgG is 
38 OOO/platelet (Fig. 1) which is similar with other CD9 
clusters such as PMA IgG (46OOO/platelet) [6] and 
AG-1 Fab (65 OOO/platelet) [7]. The high copy numbers 
of binding sites were also reported with major platelet 
membrane glycoproteins such as GPIb (25000-34000) 
[27,28] or GPIIb/IIIa (40000-50000) [29-311. 
There are a few reports that no change in molecular 
weight of p24 was found on reduction, implying that 
there are no disulphide bonds [1,14]. However, our 
data show that there is an apparent difference in 
molecular mass of both purified CD9 antigen and im- 
munoprecipitated antigen (Fig. 3B); 23000 under 
reduced and 23 500-24000 under non-reduced condi- 
tions. These results agree with earlier reports [2,11,15]. 
A failure in immunoblotting under reduced conditions 
(not shown) confirmed the existence of intramolecular 
disulfide bond(s) as suggested by others [6,7]. The dif- 
fuse appearance of the minor molecules (26- to 3 1 -kDa) 
detected by silver-stained SDS gel (Fig. 3A) and 
autoradiograms of immunoprecipitation (Fig. 3B) sug- 
gested the varying extent of glycosylation. The dif- 
ference in the binding property of the minor molecules 
to DEAE-gel (Fig. 2B) might be derived from the dif- 
ference in glycosylation. 
Although it was shown that the p24 molecule is an 
external membrane protein having no transmem- 
branous moiety [5,15-171, our results are against such 
a notion. Affinity to Triton X-114 and the 
hydrophobicity of N-terminal sequence (position 
12-20) (Fig. 4) suggest that p24 has transmembrane 
domain(s). Melanoma-associated antigen [24,25] which 
has 40% homology with p24 in N-terminal sequence (20 
amino acids), was recently cloned and shown to have 4 
transmembrane amino acid sequences including N- 
terminal region [25]. CD10 antigen (CALLA) was in- 
itially thought to have no transmembranous moiety as 
shown by photoaffinity labeling using a lipophilic pro- 
be [32]. However, the cloning of CALLA by two 
groups revealed that it has a transmembrane 
hydrophobic amino acid sequence [33,34]. Cloning of 
p24 from human platelets is currently under investiga- 
tion in our laboratory to further characterize the struc- 
ture and function of this protein. 
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